Illumina, Inc. (ILMN)-Financial and Strategic SWOT Analysis Review

Region:North America

Author(s):

Product Code:GDME3646FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

April 2017

Total pages

61

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

Illumina, Inc. (ILMN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The company's products are distributed to various countries through its distributors in Africa, Asia Pacific, Central America, Europe, the Middle East, North America, and South America. Illumina is headquartered in San Diego, California, the US.

Illumina, Inc. Key Recent Developments

Apr 20,2017: Personalis Orders Ten Illumina NovaSeq 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing

Apr 10,2017: CloudHealth Genomics Makes China's First Sequencing Data Available Using Illumina's NovaSeq 6000

Apr 03,2017: Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC

Apr 03,2017: Novogene Adds 25 Illumina NovaSeq Sequencers

Mar 28,2017: Macrogen Leads Precision Medicine by Advancing the Realization of the "$100 Genome Age"

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products


Companies

Qiagen NV Pacific Biosciences Inc Luminex Corp GenMark Diagnostics Inc Agilent Technologies, Inc. Affymetrix, Inc.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Illumina, Inc.-Key Facts 6

Illumina, Inc.-Key Employees 7

Illumina, Inc.-Key Employee Biographies 8

Illumina, Inc.-Major Products and Services 10

Illumina, Inc.-Medical Equipment Pipeline Products Data 12

Illumina, Inc. Pipeline Products by Equipment Type 12

Illumina, Inc. Pipeline Products by Development Stage 13

Illumina, Inc.-History 15

Illumina, Inc.-Company Statement 24

Illumina, Inc.-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Joint Venture 27

Section 2-Company Analysis 28

Illumina, Inc.-Business Description 28

Illumina, Inc.-Corporate Strategy 30

Illumina, Inc.-SWOT Analysis 31

SWOT Analysis-Overview 31

Illumina, Inc.-Strengths 31

Illumina, Inc.-Weaknesses 32

Illumina, Inc.-Opportunities 33

Illumina, Inc.-Threats 34

Illumina, Inc.-Key Competitors 35

Section 3-Company Financial Ratios 36

Financial Ratios-Capital Market Ratios 36

Financial Ratios-Annual Ratios 37

Performance Chart 40

Financial Performance 40

Financial Ratios-Interim Ratios 41

Financial Ratios-Ratio Charts 42

Section 4-Company's Lifesciences Financial Deals and Alliances 43

Illumina, Inc., Medical Equipment, Deals By Year, 2011 to YTD 2017 43

Illumina, Inc., Medical Equipment, Deals By Type, 2011 to YTD 2017 44

Illumina, Inc., Recent Deals Summary 45

Section 5-Company's Recent Developments 46

Apr 10, 2017: CloudHealth Genomics Makes China's First Sequencing Data Available Using Illumina's NovaSeq 6000 46

Apr 03, 2017: Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC 47

Apr 03, 2017: Novogene Adds 25 Illumina NovaSeq Sequencers 48

Feb 20, 2017: Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina 49

Jan 31, 2017: Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016 50

Jan 27, 2017: Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries 52

Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 53

Jan 09, 2017: Illumina Introduces the NovaSeq Series-a New Architecture Designed to Usher in the $100 Genome 54

Jan 03, 2017: Illumina Taps Garret Hampton, One of the World's Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit 55

Dec 20, 2016: Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Business Development, Adding Further Clinical and Life Sciences Expertise to its Executive Team 56

Section 6-Appendix 57

Methodology 57

Ratio Definitions 57

About GlobalData 61

Contact Us 61

Disclaimer 61


List of Figure

List of Figures

Illumina, Inc. Pipeline Products by Equipment Type 12

Illumina, Inc. Pipeline Products by Development Stage 13

Illumina, Inc., Performance Chart (2012-2016) 40

Illumina, Inc., Ratio Charts 42

Illumina, Inc., Medical Equipment, Deals By Year, 2011 to YTD 2017 43

Illumina, Inc., Medical Equipment, Deals by Type, 2011 to YTD 2017 44


List of Table

List of Tables

Illumina, Inc., Key Facts 6

Illumina, Inc., Key Employees 7

Illumina, Inc., Key Employee Biographies 8

Illumina, Inc., Major Products and Services 10

Illumina, Inc. Pipeline Products by Equipment Type 12

Illumina, Inc. Number of Pipeline Products by Development Stage 13

Illumina, Inc. Pipeline Products Summary by Development Stage 14

Illumina, Inc., History 15

Illumina, Inc., Other Locations 25

Illumina, Inc., Subsidiaries 25

Illumina, Inc., Joint Venture 27

Illumina, Inc., Key Competitors 35

Illumina, Inc., Ratios based on current share price 36

Illumina, Inc., Annual Ratios 37

Illumina, Inc., Annual Ratios (Cont...1) 38

Illumina, Inc., Annual Ratios (Cont...2) 39

Illumina, Inc., Interim Ratios 41

Illumina, Inc., Medical Equipment, Deals By Year, 2011 to YTD 2017 43

Illumina, Inc., Medical Equipment, Deals By Type, 2011 to YTD 2017 44

Illumina, Inc., Recent Deals Summary 45

Currency Codes 57

Capital Market Ratios 57

Equity Ratios 58

Profitability Ratios 58

Cost Ratios 59

Liquidity Ratios 59

Leverage Ratios 60

Efficiency Ratios 60

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022